Home・Akcijų sąrašas・Cerus Corp

Cerus Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

2.34 1.3

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.33

Max

2.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.3M -3M
Pardavimai	-2.5M 57M
Pelnas, tenkantis vienai akcijai	-0.01
Pelno marža	-5.191
Darbuotojai	261
EBITDA	-1.5M -712K

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+112.77% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-182M 433M
Ankstesnė atidarymo kaina	1.04
Ankstesnė uždarymo kaina	2.34

Cerus Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-07 23:56; UTC

Cerus Corp shares are higher in after-market trading, recovering from earlier declines amid shifting expectations for Federal Reserve interest rate hikes.

2026-08-06 19:46; UTC

Cerus Corp shares are higher in Thursday's session, having gained since Wednesday. The stock remains below its 20-day moving average.

2026-08-05 19:43; UTC

Cerus Corp shares are higher Wednesday, recovering from an earlier decline amid high trading volume. Broader market sentiment is influenced by ADP's employment report.

2026-08-04 19:11; UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

2026-08-03 19:56; UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

2026-07-31 23:06; UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

2026-07-30 23:41; UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

2026-07-29 19:56; UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

2026-07-28 16:02; UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

2026-07-27 20:07; UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

2026-07-24 19:06; UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

2026-07-23 09:01; UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

2026-07-22 15:46; UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

2026-07-21 21:41; UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Akcijų palyginimas

Kainos pokytis

Cerus Corp Prognozė

Kainos tikslas

By TipRanks

112.77% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 112.77%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Cerus Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Cerus Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.